Inveltys eye drops are a corticosteroid medication used to treat ocular inflammation and pain following cataract surgery [1]. They are formulated as a topical ophthalmic suspension [1].
How do Inveltys eye drops work?
Inveltys works by reducing inflammation and suppressing the immune response in the eye, which helps alleviate pain and swelling after surgery [1].
When do Inveltys eye drops' patents expire?
Information on the specific patent expiry dates for Inveltys is available through resources like DrugPatentWatch.com [2]. Patent expiration determines when generic versions of the drug may become available.
Who makes Inveltys eye drops?
Inveltys eye drops are manufactured by Eyevance Pharmaceuticals [1].
What are the potential side effects of Inveltys?
Common side effects reported with Inveltys include blurred vision, eye irritation, and changes in taste [1]. Like other corticosteroids, there is also a potential risk of increased intraocular pressure and the development of glaucoma or cataracts with prolonged use [1].
How does Inveltys compare to other post-surgery eye drops?
Inveltys is a corticosteroid, a class of drugs commonly used for post-operative ocular inflammation. Other treatments might include non-steroidal anti-inflammatory drugs (NSAIDs) or a combination of medications, depending on the specific needs of the patient and the surgeon's preference [3].
What is the clinical data supporting Inveltys?
Clinical trials have evaluated the efficacy and safety of Inveltys in patients undergoing cataract surgery, demonstrating its ability to reduce ocular inflammation and pain [1].
What is the regulatory status of Inveltys?
Inveltys has received approval from regulatory bodies, such as the U.S. Food and Drug Administration (FDA), for its indicated use in treating post-operative ocular inflammation and pain [1].
Can generic versions of Inveltys be made available?
The availability of generic versions of Inveltys depends on patent expiration and any regulatory hurdles. Once patents expire, other manufacturers may seek approval to market generic equivalents, potentially leading to lower costs [2].
Sources:
[1] https://www.eyevance.com/inveltys/
[2] https://drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962185/